DexCom, Inc. (NASDAQ:DXCM) EVP Michael Jon Brown Sells 659 Shares

DexCom, Inc. (NASDAQ:DXCM) EVP Michael Jon Brown sold 659 shares of the stock in a transaction on Friday, June 28th. The stock was sold at an average price of $114.29, for a total value of $75,317.11. Following the transaction, the executive vice president now directly owns 66,901 shares in the company, valued at approximately $7,646,115.29. The transaction was disclosed in a filing with the SEC, which is available at this link.

Michael Jon Brown also recently made the following trade(s):

• On Friday, May 31st, Michael Jon Brown sold 652 shares of DexCom stock. The shares were sold at an average price of $119.24, for a total value of $77,744.48.
• On Tuesday, April 30th, Michael Jon Brown sold 629 shares of DexCom stock. The shares were sold at an average price of $126.25, for a total value of $79,411.25.

DexCom Stock Performance

DXCM stock traded down $1.16 during trading on Friday, hitting $113.38. 5,429,403 shares of the company traded hands, compared to its average volume of 2,955,711. The stock’s 50-day simple moving average is $123.49 and its 200 day simple moving average is $125.69. The company has a debt-to-equity ratio of 1.08, a current ratio of 2.90 and a quick ratio of 2.53. The company has a market cap of $45.09 billion, a PE ratio of 72.96, a P/E/G ratio of 2.77 and a beta of 1.22. DexCom, Inc. has a 1 year low of $74.75 and a 1 year high of $142.00.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, April 25th. The medical device company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.05. DexCom had a return on equity of 31.01% and a net margin of 16.82%. The company had revenue of $921.00 million during the quarter, compared to analysts’ expectations of $911.20 million. On average, equities analysts expect that DexCom, Inc. will post 1.78 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently weighed in on DXCM. Canaccord Genuity Group raised their price objective on DexCom from $144.00 to $145.00 and gave the company a “buy” rating in a research report on Friday, April 26th. Royal Bank of Canada began coverage on DexCom in a report on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 price target for the company. UBS Group raised their price target on DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a report on Wednesday, April 10th. StockNews.com downgraded DexCom from a “buy” rating to a “hold” rating in a report on Monday, June 10th. Finally, Redburn Atlantic initiated coverage on DexCom in a research note on Thursday, May 30th. They issued a “neutral” rating and a $130.00 price objective for the company. Four investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $140.33.

Institutional Trading of DexCom

Several institutional investors have recently bought and sold shares of DXCM. Mariner LLC grew its holdings in DexCom by 6.8% in the third quarter. Mariner LLC now owns 34,518 shares of the medical device company’s stock valued at $3,221,000 after purchasing an additional 2,186 shares during the period. Cary Street Partners Investment Advisory LLC boosted its stake in shares of DexCom by 11.1% in the third quarter. Cary Street Partners Investment Advisory LLC now owns 1,153 shares of the medical device company’s stock worth $108,000 after acquiring an additional 115 shares during the last quarter. O Shaughnessy Asset Management LLC boosted its stake in shares of DexCom by 17.9% in the third quarter. O Shaughnessy Asset Management LLC now owns 15,622 shares of the medical device company’s stock worth $1,458,000 after acquiring an additional 2,371 shares during the last quarter. Teza Capital Management LLC acquired a new stake in shares of DexCom in the third quarter worth approximately $1,391,000. Finally, Sherbrooke Park Advisers LLC acquired a new stake in shares of DexCom in the third quarter worth approximately $1,087,000. 97.75% of the stock is owned by institutional investors and hedge funds.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.